Alvea is a startup biotechnology company focused on building a streamlined platform for developing and deploying DNA vaccines against COVID-19 variants and other pathogens. It launched in February 2022.[1]
Fish, Kyle (2022) Announcing Alvea—An EA COVID vaccine project, Effective Altruism Forum, February 16.
Alvea. Official website.
biosecurity | COVID-19 pandemic | pandemic preparedness | vaccines
PR Newswire (2022) Alvea launches scalable, shelf- stable DNA vaccine development against new SARS-CoV-2 variants, PR Newswire, February 16.
Apply for a job.